{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:20:00Z","timestamp":1792120800971,"version":"4.4.0"},"reference-count":59,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world, especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2% of cancer diagnoses and over 2% of cancer deaths (more than double the global proportion). Incidence has risen by 126% globally and over 40% in the US since 1990, while global mortality has risen by 94% and US mortality has fallen by 18%. The 5 year survival in the US has more than doubled over the past decades with the introduction of new targeted therapies and transplant techniques. Risk factors for MM include age (average age of diagnosis is 69), race (African Americans are over double as likely to be diagnosed), sex (men are at a 1.5\u00d7 risk), and family history. Diagnosis includes serum or urine electrophoresis and free light-chain assay but requires bone marrow biopsy. It is distinguished from smoldering myeloma and monoclonal gammopathy of undetermined significance by a high (&gt;3 g\/dL) level of M-protein (monoclonal light chains) and the presence of CRAB (Hypercalcemia, Renal failure, Anemia, Bone pain) symptoms, which include hypercalcemia, renal failure, anemia, and bone pain, suggesting an end-organ damage. International staging system staging involves beta 2 microglobulin and albumin levels, while the revised system considers prognostic factors such as lactate dehydrogenase levels and chromosomal abnormalities. Front-line management includes induction regimen, maintenance therapy and hematopoietic cell transplantation for eligible patients and bisphosphonates or bone-stimulating agents for the prevention of skeletal events. Treatment for relapsed disease includes newly approved monoclonal antibodies like the CD38-targeting daratumumab, proteasome inhibitors, immunomodulating agents, and investigational therapies such as B cell maturation antigen Chimeric antigen receptor T cells.<\/jats:p>","DOI":"10.3390\/medsci9010003","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T02:36:05Z","timestamp":1611196565000},"page":"3","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":226,"title":["Epidemiology, Staging, and Management of Multiple Myeloma"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-073X","authenticated-orcid":false,"given":"Sandeep Anand","family":"Padala","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Hypertension and Transplant, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Barsouk","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Cancer Center, Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Barsouk","sequence":"additional","affiliation":[{"name":"Hematology-Oncology, Allegheny Health Network, Pittsburgh, PA 15212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4361-8498","authenticated-orcid":false,"given":"Prashanth","family":"Rawla","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sovah Health, Martinsville, VA 24112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Vakiti","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology-Oncology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8283-2403","authenticated-orcid":false,"given":"Ravindra","family":"Kolhe","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pathology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5290-9289","authenticated-orcid":false,"given":"Vamsi","family":"Kota","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology-Oncology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germame Hailegiorgis","family":"Ajebo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology-Oncology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"ref_1","first-page":"461","article-title":"Multiple Myeloma","volume":"2","author":"Jurczyszyn","year":"2019","journal-title":"Encycl. Biomed. Gerontol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1126\/science.1164390","article-title":"Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells","volume":"322","author":"Colmone","year":"2008","journal-title":"Science"},{"key":"ref_3","first-page":"373","article-title":"Multiple Myeloma: Diagnosis and Treatment","volume":"95","author":"Michels","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-40320-5_1","article-title":"MGUS and smoldering multiple myeloma: Diagnosis and epidemiology","volume":"Volume 169","author":"Mateos","year":"2016","journal-title":"Plasma Cell Dyscrasias"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1038\/bcj.2015.28","article-title":"Waldenstrom macroglobulinemia: Prognosis and management","volume":"5","author":"Oza","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_7","unstructured":"(2020, May 07). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.fr\/today."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_10","unstructured":"Howlander, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2019). SEER Cancer Statistics Review 1975\u20132016."},{"key":"ref_11","unstructured":"(2020, May 07). SEER*Explorer, Available online: https:\/\/seer.cancer.gov\/explorer\/index.html."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/bjh.16487","article-title":"The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions","volume":"189","author":"Atkin","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: A population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2013-03-487215","article-title":"Multiethnic myeloma","volume":"121","author":"Weiss","year":"2013","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2012-07-443606","article-title":"Uncovering the biology of multiple myeloma among African Americans: A comprehensive genomics approach","volume":"121","author":"Baker","year":"2013","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: Support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjh.14199","article-title":"Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium","volume":"175","author":"Schinasi","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple Myeloma: Diagnosis and Treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated Diagnostic Criteria and Staging System for Multiple Myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for Multiple Myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2009.61","article-title":"Is the international staging system superior to the Durie\u2013Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant","volume":"23","author":"Hari","year":"2009","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"LBA-2","DOI":"10.1182\/blood-2018-120737","article-title":"Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)","volume":"132","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ajh.22237","article-title":"Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management","volume":"87","author":"Rajkumar","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.21913","article-title":"Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Rajkumar","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/ejh.12877","article-title":"Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials","volume":"98","author":"Sheng","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma","volume":"359","author":"Miguel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2007.00956.x","article-title":"Central nervous system myelomatosis: Review of the literature","volume":"80","author":"Nieuwenhuizen","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/bmt.2012.26","article-title":"Extramedullary disease in plasma cell myeloma: The iceberg phenomenon","volume":"48","author":"Wirk","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2214\/AJR.13.10856","article-title":"MRI Features of Extramedullary Myeloma","volume":"202","author":"Tirumani","year":"2014","journal-title":"Am. J. Roentgenol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/bjh.16454","article-title":"Real-world data on safety and efficacy of venetoclax-based regimens in relapsed\/refractory t(11;14) multiple myeloma","volume":"189","author":"Basali","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3324\/haematol.2020.248518","article-title":"Multiple myeloma with central nervous system relapse","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Mhaskar, R., Redzepovic, J., Wheatley, K., Clark, O.A.C., Miladinovic, B., Glasmacher, A., Kumar, A., and Djulbegovic, B. (2012). Bisphosphonates in multiple myeloma: A network meta-analysis. Cochrane Database Syst. Rev., CD003188.","DOI":"10.1002\/14651858.CD003188.pub3"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13696998.2018.1445634","article-title":"A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America","volume":"21","author":"Raje","year":"2018","journal-title":"J. Med. Econ."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf","year":"2012","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3324\/haematol.2015.124347","article-title":"Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: An interim analysis from the prospective GMMG-MM5 trial","volume":"100","author":"Merz","year":"2015","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ajh.25764","article-title":"Treatment and disease-related complications in multiple myeloma: Implications for survivorship","volume":"95","author":"Chakraborty","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_51","unstructured":"Vakiti, A., Padala, S.A., and Mewawalla, P. (2020, May 07). Myeloma Kidney, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499952\/."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1038\/bcj.2015.20","article-title":"Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma","volume":"5","author":"Gonsalves","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_53","unstructured":"Vakiti, A., and Mewawalla, P. (2020, May 07). Malignancy-Related Hypercalcemia, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482423\/."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/ajh.25134","article-title":"Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma","volume":"93","author":"Leleu","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1056\/NEJM200305013481822","article-title":"Reversible Dementia Due to Thalidomide Therapy for Multiple Myeloma","volume":"348","author":"Morgan","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: A population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: A systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/9\/1\/3\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:13:02Z","timestamp":1760159582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/9\/1\/3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["medsci9010003"],"URL":"https:\/\/doi.org\/10.3390\/medsci9010003","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]}}}